Back to top

Analyst Blog

Emerging pharmaceutical firm Adamis Pharmaceuticals Corporation has recently acquired the exclusive license to 3M Company's (MMM - Analyst Report) Taper Dry Powder Inhaler (DPI) technology. With an additional payment, Adamis will also be entitled to acquire this technology currently under development phase. According to the agreement, Adamis made an initial payment to exclusively license the Taper technology through Dec 31, 2013 and will make an additional payment before the same date to fully acquire the Taper technology.

The DPI technology will be used for the treatment of asthma and chronic obstructive pulmonary disease (COPD). This technology can be used with single or combination drugs and is very competitive in comparison to other similar products available in the market.

3M remains focused on inventing new products and maintaining its competitive advantage worldwide. The rise in demand for such innovative 3M product services and technology is likely to augment its overall revenues. 3M is one of the leaders to develop this novel inhalation drug delivery technology and has more than 50 years of expertise in this field.

With this acquisition, Adamis will be able to strengthen its respiratory product pipeline. The exclusive license and acquisition of the 3M Taper DPI technology provide Adamis with an opportunity in the branded generic asthma/COPD market and is expected to help the company to generate additional returns for its shareholders. GlaxoSmithKline's (GSK) Advair Diskus is a competitor of the Taper technology. Data from IMS Health put the global asthma and COPD prescription market at $34 billion with a 7% annual growth rate.

Together with its subsidiaries, 3M operates as a diversified technology company with manufacturing operations across 70 countries worldwide. In the last reported quarter,3M Company reported record net sales of $7.8 billion, improving from $7.5 billion in the year-ago quarter.

3M currently has a Zacks Rank #3 (Hold).  Other stocks that look promising and are worth a look now are ITT Corporation (ITT - Analyst Report) and United Technologies Corp (UTX - Analyst Report), each carrying a Zacks Rank #2 (Buy).

 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
PLANAR SYST… PLNR 4.44 +5.21%
BITAUTO HOL… BITA 81.71 +5.12%
CTPARTNERS… CTP 16.66 +4.26%
CHINA BIOLO… CBPO 47.91 +3.30%
MALLINCKROD… MNK 72.94 +2.85%